Latest P53 Stories
BEVERLY, Mass., March 21, 2011 /PRNewswire/ -- Cellceutix Corporation (OTCQB: CTIX), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat severe medical conditions including drug-resistant cancers, today announced that it will be presenting a poster titled "Kevetrin(TM), A Novel Small Molecule, Activates p53, Enhances Expression of p21, Induces Cell Cycle Arrest and Apoptosis in a Human Cancer Cell Line" at the American Association for Cancer...
Jean-Christophe Marine (VIB, K.U.Leuven) strongly argues against the use of Cop1-inhibitory drugs.
Mutations in three pathways important for suppressing tumors cooperate to launch glioblastoma, an aggressive brain tumor that strikes children and adults.
Burkitt's lymphoma is one of the most aggressive tumors affecting humans.
BEVERLY, Mass., March 7, 2011 /PRNewswire/ -- Cellceutix Corporation (OTCQB: CTIX) today reported that its flagship cancer compound, Kevetrin(TM), has demonstrated potent anti-tumor activity in the treatment of leukemia cells in a hematopoietic xenograft tumor model.
The gene for the protein p53 is the most frequently mutated in human cancer.
BEVERLY, Mass., March 2, 2011 /PRNewswire/ -- Cellceutix Corporation (Pink Sheets: CTIX) today announced that it has received more data on Kevetrin(TM), the Company's flagship compound for the treatment of cancers.
A small difference in DNA sequence predicts the degree of disability after a stroke.
SAN ANTONIO, Feb. 28, 2011 /PRNewswire/ -- Advanced Cell Diagnostics, Inc. (ACD) today announced the results of its clinical study utilizing RNAscope(TM) technology to detect human papillomavirus (HPV) E6/E7 mRNA in routine clinical specimens of head and neck cancer.
Like a bounty hunter returning escapees to custody, a cancer-fighting gene converts organ cells that change into highly mobile stem cells back to their original, stationary state.
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.